Insight, China's Pharmaceutical Industry

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Edding Genor Group Holdings Limited (HKG: 6998) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026

Hengrui Pharmaceuticals (SHA: 600276; HKG: 1276) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Fineline Cube Jul 3, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary Megalith has entered into a...

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026

Bio-sincerity (SHE: 301096) announced that China’s National Medical Products Administration (NMPA) has approved its investigational...

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Fineline Cube Jul 3, 2026

Novartis AG (NYSE: NVS) announced that the European Commission (EC) has granted marketing authorization for...

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Fineline Cube Jul 3, 2026

Ocumension Therapeutics (HKG: 1477) announced that China’s National Medical Products Administration (NMPA) has approved the...

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Fineline Cube Jul 3, 2026

Hotgen Biotech (SHA: 688068) has officially registered Beijing Shangjing Zhiyao Technology Co., Ltd., a wholly-owned...

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026

Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has...

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026

Junshi Biosciences (HKG: 1877, SHA: 688180) announced a licensing agreement with Fosun Wanbang Pharma Group,...

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026

Jingxin Pharmaceutical (SHE: 002020) announced that China’s National Medical Products Administration (NMPA) has approved the...

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Fineline Cube Jul 2, 2026

TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced the completion of patient enrollment in the...

Company Drug

TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile

Fineline Cube Jul 2, 2026

TransThera (Nanjing) Technology Co., Ltd. (HKG: 2617) announced that China’s National Medical Products Administration (NMPA)...

Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026

Insilico Medicine (HKG: 3696) announced a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TYO:...

Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026

Nona Biosciences and Lonza Group Ltd. (SWX: LONN) announced a strategic collaboration to jointly develop...

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Fineline Cube Jul 2, 2026

Juventas Cell Therapy Ltd. announced that the New Drug Application (NDA) for Yuanruida (inaticabtagene autoleucel),...

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026

Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) and Memo Therapeutics AG jointly announced a definitive share...

Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Fineline Cube Jul 2, 2026

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026

Ribo Life Science (HKG: 6938) announced the achievement of its first development milestone—selection of a...

Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026

Abbisko Therapeutics (HKG: 2256) announced a strategic collaboration agreement with AstraZeneca plc (NYSE: AZN) to...

You Missed